Law review articles:
Christopher J. Morten & Amy Kapczynski, The Big Data Regulator, Rebooted: Why and How the FDA Can and Should Disclose Confidential Data on Prescription Drugs, 109 Calif. L. Rev. __ (forthcoming 2021).
Christopher J. Morten & Charles Duan, Who’s Afraid of Section 1498? A Case for Government Patent Use in Pandemics and Other National Crises, 22 Yale J.L. & Tech. __ (forthcoming 2020).
Mark J. Abate & Christopher J. Morten, Standing with a Bundle of Sticks: The All Substantial Rights Doctrine in Action, 28 Fordham Intell. Prop. Media & Ent. L.J. 477 (2018).
Shorter articles, essays, and blog posts:
Chris Morten, XOXO Science, in 1996 (Matt Keegan ed., 2020).
Christopher Morten & Charles Duan, Who’s Afraid of Section 1498?: Government Patent Use as Versatile Policy Tool, guest post on Written Description (April 24, 2020).
Christopher J. Morten, Amy Kapczynski, Harlan M. Krumholz & Joseph S. Ross, To Help Develop The Safest, Most Effective Coronavirus Tests, Treatments, And Vaccines, Ensure Public Access To Clinical Research Data, Health Affairs Blog (March 26, 2020).
Matthew Herder, Christopher J. Morten & Peter Doshi, Integrated Drug Reviews at the US Food and Drug Administration—Legal Concerns and Knowledge Lost, 180(5) JAMA Intern Med 629-30 (March 2, 2020), doi:10.1001/jamainternmed.2020.0074.
- FDA’s response: Comment & Response of Janet Woodcock, Peter Stein & Kevin Bugin.
- Our reply: Comment & Response of Peter Doshi, Christopher J. Morten & Matthew Herder.
Christopher J. Morten, Aaron S. Kesselheim & Joseph S. Ross, The Supreme Court’s Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation, 47 Journal of Law, Medicine & Ethics 783 (January 19, 2020).
Alexander C. Egilman, Joshua D. Wallach, Christopher J. Morten, Peter Lurie & Joseph S. Ross, Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017, 4 Research Integrity & Peer Review 26 (2019).
Christopher J. Morten & Amy Kapczynski, United States v. Gilead: Can a Lawsuit Yield Better Access To PrEP?, Health Affairs Blog (November 18, 2019).
Christopher J. Morten & Amy Kapczynski, Assessing Drug Pricing Reform Proposals: The Real Leverage and Benefits of Competitive Licensing, Health Affairs Blog (November 4, 2019).
Cynthia Lambert Hardman, Marta E. Delsignore & Christopher J. Morten, Forum Selection Clauses Can Doom PTAB Review, Law360 (April 20, 2018).
Cynthia Lambert Hardman, Marta E. Delsignore & Christopher J. Morten, Inter Partes Review Estoppel Takes Shape, Law360 (January 9, 2017).
Christopher Morten, Motion Practice In Inter Partes Review, Lexology (Aug. 19, 2014).
Op eds and advocacy:
Christopher Morten, To Invent Our Way Beyond COVID-19, We Need Open Science, Common Dreams (Sept. 17, 2020).
Dana Brown & Christopher Morten, Four Steps to Transform the Pharmaceutical Industry and Survive the Pandemic, In These Times (Sept. 10, 2020).
Dana Brown, Alex Lawson, Christopher Morten & Fran Quigley, Reclaim Public Medicine for Public Health, Common Dreams (Aug. 20, 2020).
- also published at PublicMedicines.org.
Carrie Teicher & Christopher J. Morten, We need strings attached!, Medium (Aug. 5, 2020).
Christopher Morten, Christian Urrutia & James Krellenstein, A powerful law gives HHS the right to take control of remdesivir manufacturing and distribution, STAT (July 2, 2020).
Chris Morten & Alex Moss, Could a patent get in between you and a Covid-19 test? Yes, The Guardian (May 20, 2020).
Christopher Morten & Charles Duan, The tension between public health and patents in the era of Covid-19, STAT (April 14, 2020).
Christopher Morten, Peter G. Lurie & Charles Seife, Lost opportunities from FDA, NIH inaction when sponsors fail to report clinical trial results, STAT (April 13, 2020).
Shweta Kumar, Christopher Morten & Joseph J. Ross, Promoting clinical trial transparency through the courts: A strategic lawsuit against the FDA, TranspariMED Blog (Oct. 23, 2019).
Letter to the editor:
Christopher J. Morten & Peter Maybarduk, letter to the editor re “The Remdesivir Patent Isn’t State Property,” The Wall Street Journal (Sept. 8, 2020).